Cardiomyocyte sulfonylurea receptor 2-KATP channel mediates cardioprotection and ST segment elevation

Douglas A Stoller1, John P Fahrenbach, Karel Chalupsky

  • 1Committee on Cellular and Molecular Physiology, University of Chicago, Chicago, IL 60637, USA.

Insights

Restoring cardiomyocyte SUR2-K(ATP) channels in SUR2 null mice reduced heart infarct size and improved cardiac function. This highlights the role of these channels in cardioprotection and reducing ST segment elevation.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Ion Channel Biology

Background:

  • Sulfonylurea receptor-containing ATP-sensitive potassium (K(ATP)) channels are linked to cardioprotection, but their specific cellular roles remain unclear.
  • SUR2 null mice, lacking full-length SUR2, exhibit ST segment elevation and coronary artery vasospasm.
  • Understanding the precise contribution of cardiomyocyte SUR2-K(ATP) channels is crucial for elucidating cardioprotective mechanisms.

Purpose of the Study:

  • To investigate the role of cardiomyocyte SUR2-K(ATP) channels in cardioprotection.
  • To determine if restoring SUR2A expression in cardiomyocytes of SUR2 null mice can mitigate cardiac damage and dysfunction.
  • To analyze the impact of cardiomyocyte SUR2-K(ATP) channel restoration on electrocardiographic changes.

Main Methods:

  • Generation of transgenic mice (MLC2A) with cardiomyocyte-restricted expression of SUR2A in a SUR2 null background.
  • Assessment of infarct size and cardiac function during post-ischemia reperfusion in isolated hearts.
  • Monitoring of electrocardiographic changes, specifically ST segment elevation, in the different mouse models.

Main Results:

  • Restoration of functional cardiac K(ATP) channels in MLC2A mice.
  • Significantly reduced infarct size in MLC2A hearts (27%) compared to SUR2 null hearts (36%).
  • Improved cardiac function and preserved low diastolic pressures in MLC2A hearts during reperfusion, along with reduced ST segment elevation.

Conclusions:

  • Cardiomyocyte SUR2-K(ATP) channels play a significant role in cardioprotection, reducing infarct size and improving post-ischemic function.
  • Restoration of these channels mitigates ST segment elevation, suggesting a link to vasospasm.
  • Both SUR2-K(ATP) channel-dependent and -independent mechanisms contribute to overall cardiac function and protection.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...